IngredientsHeyndrickxia coagulans (formerly Bacillus coagulans) is a lactic acid–forming bacterial species that was transferred to the genus Weizmannia in 2020, then to Heyndrickxia in 2023. The name Bacillus coagulans remains dominant in regulatory documentation, dietary supplement labeling, and the vast majority of peer-reviewed literature; both names will be used interchangeably throughout this article.
The species was first isolated and described in 1915 by B.W. Hammer at the Iowa Agricultural Experiment Station as a cause of an outbreak of coagulation in evaporated milk packed by an Iowa condensery. Separately isolated in 1935 and described as Lactobacillus sporogenes in the fifth edition of Bergey's Manual of Systematic Bacteriology, it exhibits characteristics of both genera. It should be noted that Bacillus coagulans had previously been mischaracterized as a Lactobacillus in view of the fact that, as originally described, this bacterium was labeled as Lactobacillus sporogenes (Nakamura et al. 1988, Int. J. Syst. Bacteriol. 38: 63–73). Initial classification was incorrect due to the fact that Bacillus coagulans produces spores and through metabolism excretes L(+)-lactic acid; these developmental and metabolic aspects required that the bacterium be classified as a lactic acid bacillus, and therefore it was re-designated.
In 2020, a major taxonomic revision led to the establishment of the genus Weizmannia. This revision was based on genomic studies that revealed Bacillus coagulans had significant genetic differences from the core Bacillus species, particularly in traits related to spore formation and metabolic processes. Subsequent genetic analyses in 2023 revealed similarities between the genera Weizmannia and Heyndrickxia, leading to the reclassification of all Weizmannia species under the genus Heyndrickxia. Therefore, the current and formally accepted name of this bacterium is Heyndrickxia coagulans.
H. coagulans is a catalase-positive, spore-forming, motile, facultative anaerobe, rod-shaped microbe, usually Gram-positive when a Gram stain test is performed; however, if the Gram stain is performed while H. coagulans is entering the stationary phase of growth, the microbe may appear Gram-negative. It exhibits facultative anaerobiosis, with cylindrical cells featuring blunt ends that occur singly, in pairs, or in short chains, and it forms oval endospores typically at the poles of the cells.
H. coagulans grows best at 50 °C (122 °F), but the microbe can sustain growth on a temperature range of 30–55 °C (86–131 °F). Optimal growth occurs at temperatures between 30–50 °C and pH levels of 5.5–6.5, during which it ferments carbohydrates such as maltodextrin, mannitol, raffinose, sucrose, and trehalose without producing gas.
The bacterium H. coagulans has been found in various environments including an array of different fruits and vegetables such as potatoes, pickles, and corn. In addition, H. coagulans appears in fermented rice and soil. Various strains of Bacillus coagulans can also be isolated from natural sources (e.g., heat-treated soil samples) using well-known procedures (see Bergey's Manual of Systematic Bacteriology, Vol. 2, p. 1117, Sneath et al., Williams & Wilkins, Baltimore, Md., 1986). It is also naturally present in certain fermented foods; fermented foods like yogurt, kefir, sauerkraut, and kombucha are a source of Bacillus coagulans.
Multiple well-characterized commercial strains exist and have been used in clinical research. The most frequently studied include:
The traditional use of probiotics in dairy products for human consumption has a long history in several parts of the world. Bacillus coagulans specifically was not identified as a distinct probiotic organism until the early 20th century. Bacillus coagulans was first identified in 1915 by Hammer from spoiled canned milk; however, some strains were misclassified as Lactobacillus sporogenes. In 1933, Horowitz-Wlassowa and Nowotel reclassified Lactobacillus sporogenes under the genus Bacillus.
Bacillus coagulans strains have been used as animal feed additives for poultry and livestock to reduce disease and improve feed utilization and, therefore, to increase growth rate in the animals (International PCT Patent Applications No. WO 9314187 and No. WO 9411492). In particular, Bacillus coagulans strains have been used as general nutritional supplements and agents to control constipation and diarrhea in humans and animals.
Some strains of Bacillus coagulans alongside other probiotic Bacillus strains are widely available in Indian markets and popularly prescribed for use as an adjunct with antibiotic therapy to prevent antibiotic-induced diarrhea and gastrointestinal disorders. Systematic clinical investigation of the organism began in earnest in the late 1990s and 2000s, reflecting a broader scientific and commercial interest in spore-forming probiotics.
Bacillus coagulans is a Gram-positive rod that forms central to subterminal endospores containing dipicolinic acid and small acid-soluble spore proteins that protect DNA during heat, acid, and desiccation. Cell structure includes a thick peptidoglycan, teichoic acids, surface proteins, and polysaccharides that mediate adhesion and immune signaling.
Key metabolites include primarily L-lactic acid via lactate dehydrogenase; some strains produce bacteriocins and may influence short-chain fatty acid (SCFA)-producing consortia. Overall, B. coagulans strains have been shown to produce lactic acid, bacteriocins, digestive enzymes, short chain fatty acids, and vitamins.
Different B. coagulans strains produce varying bacteriocins; the I4 strain produces the substance coagulin; ATCC 7050 produces a novel antimicrobial peptide lactosporin; both of which showed distinct antimicrobial activity. A strain of B. coagulans BDU3, isolated from fermented fish, generates a distinct bacteriocin with a wide range of antimicrobial spectrum. Bacteriocin secreted from B. coagulans had an inhibitory effect against Escherichia coli NCTC-10418, Pseudomonas aeruginosa NCIB-9016, Klebsiella pneumoniae NCIB-9111, B. subtilis NCTC-6346, Staphylococcus aureus NCTC7447, and fungi such as Candida albicans CBS-562.
B. coagulans also produces butyric acid, a short-chain fatty acid, that aids in the healing process of cells in the small and large intestines. Integrating B. coagulans spores has other advantages, including the generation of bacteriocins, peptides, fatty acids with a short chain, riboflavin, and hydrogen peroxide.
H. coagulans also secretes specialized adhesion proteins, including mucins and fibrinogen-binding proteins, which facilitate colonization in the gut and reduce pathogenic adhesion.
The fundamental challenge facing any probiotic is delivery: the organism must survive the acidic environment of the stomach (pH 1.5–3.5), endure exposure to bile salts in the small intestine, and arrive at the colon viable and in sufficient numbers to exert its effects. B. coagulans uniquely addresses this challenge through its spore-forming nature. B. coagulans is well known for its spore-forming ability; the spores can survive harsh conditions including high temperatures, acidity, and pressures. Once these resilient spores safely navigate the stomach and enter the duodenum, the environment shifts. The pH becomes more neutral, and the presence of bile salts and nutrients signals the spores that it is safe to germinate. Within four to six hours, the spores germinate, transforming back into active, vegetative bacterial cells.
The inhibitory capabilities of H. coagulans are primarily realized through two modes: "competitive exclusion" and "colonization resistance." The production of bacteriocins and pediocins during its growth not only directly inhibits the growth of pathogenic bacteria but also participates in the regulation of the gut environment as quorum-sensing molecules. B. coagulans reduces the availability of nutrients and space that can be used by harmful bacteria (competitive exclusion). This specific mode of action includes the production of a broad range of digestive enzymes, which also optimizes feed conversion and efficiency. The production of specific growth-inhibiting compounds and lactic acid-driven hydrogen protons can directly reduce the abundance of harmful bacteria.
B. coagulans can secrete lactic acids and anti-bacterial substances, which reduce the intestinal pH to a value unfavorable for the growth of harmful bacteria. Consequently, the balance of gut microbiota is restored, and intestinal peristalsis is promoted.
The mechanisms by which spore-forming probiotics such as Bacillus coagulans could enhance health of the host include stimulation of the immune system, synthesis of different antimicrobials like bacteriocins, enzymes, and modulation of the composition of gut microbiota. The germinated spores were found to be highly immunogenic; both the cell wall and metabolite fractions contributed significantly. Under normal culture conditions, increased levels of immune activation were observed as increased expressions of CD25 and CD69 relative to natural killer cells, suggesting an increased ability to attack virus-infected target cells. The complex interaction between the microbiota and the host immune system can be modulated by probiotic lactic acid production but also by probiotic-associated cell surface molecules. In this indirect way, a probiotic-boosted immune system leads to an enhanced immune defense against harmful bacteria and viruses.
Its facultative anaerobic nature allows it to form spores under specific conditions and rapidly germinate into vegetative cells in the gastrointestinal tract, thereby promoting the growth and colonization of beneficial bacteria such as Lactobacillus and Bifidobacterium.
Microbes are an important link for the communication of the gut–brain axis, and the alteration of the gut–brain axis by certain interventions may be a potential strategy for the management of comorbid central nervous system (CNS) disorders. Preliminary human data suggest B. coagulans may influence this axis (see Section 5.5 below).
IBS represents the most extensively studied application of B. coagulans in human clinical trials.
Study 1 — GBI-30, 6086 (general IBS, 44 subjects): A preliminary controlled study was conducted to evaluate the effects of the probiotic Bacillus coagulans GBI-30, 6086 on IBS symptoms. This was a randomized, double-blind, parallel-group, placebo-controlled clinical trial involving 44 subjects who received either placebo or B. coagulans GBI-30, 6086 once a day for 8 weeks. Preliminary data suggest that the patented B. coagulans GBI-30, 6086 probiotic may be a safe and effective option for the relief of abdominal pain and bloating for patients with IBS. Larger, extended trials are needed to verify these results.
Study 2 — GBI-30, 6086 (diarrhea-predominant IBS, 52 subjects): This pilot study evaluated effects of the proprietary GanedenBC(30) (Bacillus coagulans GBI-30, 6086) probiotic in a randomized, double-blind, placebo-controlled clinical trial including patients with diarrhea-predominant IBS (IBS-D). Patients were randomized to receive either B. coagulans GBI-30, 6086 or placebo once a day for 8 weeks. Of the remaining 52 patients with IBS-D, the average number of bowel movements per day was significantly reduced for patients treated with B. coagulans GBI-30, 6086 when compared to placebo (P = 0.042).
Study 3 — MTCC 5856 (diarrhea-predominant IBS, 36 subjects): Thirty-six newly diagnosed diarrhea-predominant IBS patients were enrolled in three clinical centres. Along with standard care of treatment, 18 patients received placebo while 18 patients received B. coagulans MTCC 5856 tablet containing 2 × 109 CFU/day as active for 90 days. Participants receiving B. coagulans MTCC 5856 at 2 × 109 CFU/day for 90 days experienced statistically significant improvements compared to placebo across every primary endpoint: bloating (p = 0.0037), diarrhea (p = 0.0026), abdominal pain (p = 0.0001), and stool frequency (p = 0.0031).
Study 4 — Unique IS2 (adult IBS, 136 subjects): Patients (n = 153) fulfilling Rome III criteria were provided placebo capsules for a 2-week run-in period. Only patients satisfying compliance criteria (n = 136) were randomized (double blind) to receive either B. coagulans Unique IS2 (2 billion CFU) or placebo capsules daily for 8 weeks. Reduction of abdominal discomfort/pain intensity and increase in complete spontaneous bowel movements were analyzed as primary end points.
Study 5 — BCP92 (multicenter IBS, 100 subjects): This randomized controlled trial included 100 participants. Various parameters such as IBS severity, digestive symptom frequency, gastrointestinal symptom frequency, stool consistency, interleukin-6 levels, stress relief, and anxiety levels were evaluated over 12 weeks. B. coagulans BCP92 significantly improved IBS severity (P < .001) and gastrointestinal symptom frequency (P < .001) compared with that in the control group. Stool consistency significantly improved (P < .001). Mental stress relief was remarkable (P = .001), differentiating the test and control groups.
Study 6 — Synbiotic formulation (IBS, 85 subjects): Adult IBS patients (n = 85) were randomized to receive a synbiotic containing Bacillus coagulans or placebo for 12 weeks. Frequency of IBS symptoms including abdominal pain (scored 1 to 7), and diarrhea and constipation (scored 1 to 5) was evaluated before and after the intervention and then after a nine-month follow-up. Bacillus coagulans improves abdominal pain and diarrhea in IBS patients. Further studies on a larger sample of patients are warranted.
Evidence strength for IBS: Multiple small-to-medium-sized randomized, double-blind, placebo-controlled trials consistently report benefits for abdominal pain, bloating, and stool consistency. However, most trials have small sample sizes, use different strains and doses, and relatively short durations. The body of evidence is promising but not yet of sufficient scale or homogeneity to support definitive clinical guidelines.
Lactic acid-producing bacteria (LAB) probiotics demonstrate immunomodulating and anti-inflammatory effects and the ability to lessen the symptoms of arthritis in both animals and humans. A randomized, double-blind, placebo-controlled, parallel-design clinical pilot trial was conducted to evaluate the effects of the LAB probiotic preparation Bacillus coagulans GBI-30, 6086 on symptoms and measures of functional capacity in patients with rheumatoid arthritis (RA) in combination with pharmacological anti-arthritic medications.
Forty-five adult men and women with symptoms of RA were randomly assigned to receive Bacillus coagulans GBI-30, 6086 or placebo once a day in a double-blind fashion for 60 days in addition to their standard anti-arthritic medications. Arthritis activity was evaluated by clinical examination, the American College of Rheumatology (ACR) criteria, the Stanford Health Assessment Questionnaire Disability Index (HAQ-DI), and laboratory tests for erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Subjects who received Bacillus coagulans GBI-30, 6086 experienced borderline statistically significant improvement in the Patient Pain Assessment score (P = .052) and statistically significant improvement in Pain Scale (P = .046) vs. placebo. Compared with placebo, treatment resulted in greater improvement in patient global assessment and self-assessed disability; reduction in CRP; as well as the ability to walk 2 miles, reach, and participate in daily activities. There were no treatment-related adverse events reported throughout this study. Results of this pilot study suggest that adjunctive treatment with Bacillus coagulans GBI-30, 6086 appeared to be safe and effective for patients suffering from RA. Because of the low study population size, larger trials are needed to verify these results.
The suggested mechanism of action for this probiotic in RA is related to the anti-inflammatory properties of the bacteria. B. coagulans produces proteins known as bacteriocins and lactic acid that lower local pH levels. This process may eliminate some of the microbes that contribute to an inflammatory response in the host. B. coagulans also produces butyric acid, a short-chain fatty acid, that aids in the healing process of cells in the small and large intestines. These immunomodulating and anti-inflammatory properties may explain the ability of B. coagulans to alleviate RA.
Evidence strength for RA: A single small (n = 45) pilot RCT provides preliminary support. Results are encouraging but the evidence base is insufficient for clinical recommendations without larger replication trials.
A study was conducted to assess the safety and efficacy of the probiotic strain Bacillus coagulans MTCC 5856 for major depressive disorder (MDD) in IBS patients. Patients (n = 40) diagnosed for MDD with IBS were randomized (1:1) to receive placebo or B. coagulans MTCC 5856 at a daily dose of 2 × 109 CFU (2 billion spores) and were maintained to the end of double-blind treatment (90 days). Changes from baseline in clinical symptoms of MDD and IBS were evaluated through questionnaires.
Significant change (p = 0.01) in favour of the B. coagulans MTCC 5856 was observed for the primary efficacy measure Hamilton Rating Scale for Depression (HAM-D), Montgomery-Asberg Depression Rating Scale (MADRS), Center for Epidemiological Studies Depression Scale (CES-D), and Irritable Bowel Syndrome Quality of Life Questionnaire (IBS-QOL). Secondary efficacy measures including the Clinical Global Impression-Improvement rating Scale (CGI-I) and the Gastrointestinal Discomfort Questionnaire (GI-DQ) also showed significant results (p = 0.01) in the B. coagulans MTCC 5856 group compared to the placebo group. Serum myeloperoxidase, an inflammatory biomarker, was also significantly reduced (p < 0.01) when compared with the baseline and end of the study. All safety parameters remained well within the normal clinical range and had no clinically significant difference between the screening and end of the study.
Evidence strength for depression: This represents a single small pilot RCT (n = 40) in a specialized comorbid IBS-MDD population. While statistically significant results were reported, this study cannot be generalized to broader psychiatric populations without substantially larger replication trials.
Probiotics, particularly spore-forming strains, demonstrate potential for improving natural killer (NK) cell function and mucosal immunity through gut-associated lymphoid tissue interactions. A randomized, double-blind, placebo-controlled clinical trial evaluated the immunomodulatory effects of B. coagulans SNZ 1969® in adults. The trial was conducted over a 12-week treatment period, followed by a two-week safety follow-up.
This trial enrolled adults aged 60–65 years who were susceptible to seasonal infections. Participants were randomized 1:1 to receive either B. coagulans SNZ 1969® (2 billion CFU/day) or placebo for 12 weeks. B. coagulans SNZ 1969® significantly enhanced NK cell activity compared to placebo, with a net increase of 42.07% between groups (44.59% versus 2.52% increase from baseline; p = 0.0002). Significant improvements were observed in serum IgA (25.00% versus 2.30% change; p = 0.0016) and salivary IgA (27.70% versus 0.60% change; p = 0.0002). No significant changes occurred in absolute NK cell counts, serum IgM, IgG, or C-reactive protein levels. Secondary analyses showed numerical reduction trends in upper respiratory tract infections (20% versus 32%; p = 0.11).
Evidence strength for immune function: Mechanistically plausible and supported by one RCT showing NK cell and immunoglobulin improvements. The reduction in respiratory infections did not reach statistical significance. Evidence is preliminary.
A trial evaluated the activity and tolerability of a probiotic mix of Bacillus subtilis HU58 plus Bacillus coagulans SC208 in combination and Bacillus coagulans SC208 alone compared with placebo in a group of 75 patients suffering from Antibiotic-Associated Diarrhea (AAD). Stool consistency was estimated according to the Bristol Stool Chart and was recorded at baseline, 3rd, 7th, and 15th days, along with other symptoms like abdominal pain, bloating, and flatulence. All enrolled patients were orally administered either a cocktail of B. subtilis HU58 + B. coagulans SC208 (3 × 109 CFU/cap), or B. coagulans SC208 (2 × 109 CFU/cap) alone, or placebo.
Several strains are widely available in Indian markets and are popularly prescribed for use as an adjunct with antibiotic therapy to prevent antibiotic-induced diarrhea and gastrointestinal disorders.
Evidence strength for AAD: Supportive but limited to small open-label and controlled pilots. The overall evidence base for this indication, while consistent in direction, requires larger high-quality RCTs.
Common galenic forms include capsule/tablet with lyophilized spores, microencapsulated spores, powdered sachets, and food-incorporated spores (bars, beverages). Bacillus coagulans MTCC 5856 can withstand high temperature and is found to be stable during processing and storage conditions of functional foods such as baked foods and brewed coffee. However, Bacillus coagulans GBI-30 spores can survive heating in water at 85 degrees C (185 degrees F) for 3 minutes, though viability is lost at boiling temperature (100 degrees C / 212 degrees F).
Doses across clinical trials are reported as colony-forming units (CFU) of viable spores per day. The following doses have been documented in specific peer-reviewed trials:
The active product B. coagulans MTCC 5856, 2 billion spores per tablet (2 × 109 spore/tablet), was supplied by Sabinsa Corporation, Utah, USA. Each active tablet contained 333.33 mg of B. coagulans MTCC 5856, 222.67 mg of microcrystalline cellulose, 10 mg of starch, 30 mg of sodium starch glycolate, and 4.0 mg of magnesium stearate.
Bacillus coagulans is a Gram-positive, aerobic or facultatively anaerobic, spore-forming, lactic acid-producing bacterium identified as GRAS (Generally Recognized as Safe) (EFSA, 2013). B. coagulans MTCC 5856 is a room-temperature-stable, lactose-free, and non-GMO probiotic preparation with GRAS status.
No evidence of toxicity was observed in tested rats even at the highest dose. The calculated NOAEL is 1948 mg/kg, which means that chronic consumption of B. coagulans GBI-30, 6086 in doses up to 9.38 × 1010 CFU per day is safe. Furthermore, no sign of toxicity in the parental generation (male or female) and the F1 offspring was observed in the reproduction toxicity study. Except for two antibiotic resistance genes that were not easy to transfer, no other genes with potential safety risks were retrieved in the genome of B. coagulans GBI-30, 6086.
Recent study suggested that B. coagulans MTCC 5856 did not alter either genetically or phenotypically and was found to be consistent over multiple years of commercial production.
There were no treatment-related adverse events reported throughout the RA pilot trial. All safety parameters in the MDD-IBS trial remained well within the normal clinical range and had no clinically significant difference between screening and the end of the study. Bacillus coagulans MTCC 5856 was found to be safe and tolerable at a dose of 2 × 109 CFU (spores)/day in humans.
Hemolytic activity and lecithinase production did not occur in assessed strains. Strain identification has been confirmed through morphological, cultural, and genomic analyses including 16S RNA and whole genome sequencing to assess antimicrobial resistance and virulence factors. Phenotypic tests, such as disk diffusion for antimicrobial resistance and safety assays for cytotoxicity and hemolytic activity, have been conducted.
H. coagulans exhibits weak adhesion to intestinal epithelial cells, which prevents long-term colonization and typically results in clearance through defecation within 4–7 days. Continuous supplementation is required to maintain its probiotic effects, which could impact patient compliance.
No large-scale systematic safety studies have been conducted specifically in immunocompromised individuals or pregnant populations; available RCTs have uniformly enrolled healthy or otherwise defined adult populations. As per FAO/WHO, probiotics are defined as "live microorganisms which, when administered in adequate amounts, confer a health benefit on the host" (FAO/WHO 2002). Probiotic use in severely immunocompromised individuals requires particular attention due to the theoretical risk associated with live-organism supplementation in this population, a consideration applicable across all probiotic species.
Because B. coagulans is commonly used as an adjunct to antibiotic therapy to prevent AAD, the timing of administration relative to antibiotic dosing is a practical consideration. B. coagulans is more stable in the acidic stomach environment, can grow and sporulate with high efficiency in anaerobic conditions in the gastrointestinal tract, and form biofilms which enhance gut colonization. Because spores are highly resistant to many environmental stressors, co-administration with antibiotics is a recognized use case, though specific drug–organism interaction data from well-controlled trials are limited.
Health conditions that Bacillus coagulans may help support.
Bacillus coagulans strains (particularly MTCC 5856 and Unique IS2) have demonstrated efficacy in improving IBS symptoms in meta-analyses. A 2025 strain-specific systematic review with meta-analysis confirmed B. coagulans Unique IS2 improves key IBS symptoms including abdominal discomfort.
A 12-week RCT (n=100) using B. coagulans BCP92 showed significant reduction in anxiety levels in IBS patients. An 8-week pilot RCT (n=79) with W. coagulans BC99 showed HAMA scores reduced by 5.53 points more than placebo, with regulation of inflammatory cytokines and neurotransmitter levels. Animal studies further support anxiolytic effects via the gut-brain axis.
A double-blind, placebo-controlled RCT in RA patients (n=45) showed B. coagulans GBI-30, 6086 produced significant pain reduction and functional improvements as an adjunct to standard therapy. LAB probiotics including B. coagulans demonstrate immunomodulating and anti-inflammatory effects in both animal and human arthritis models.
A crossover RCT showed B. coagulans GBI-30, 6086 + casein prevented the decline in Wingate peak power observed in the protein-only group following muscle-damaging exercise. Improved protein absorption (BCAAs) and gut-muscle axis modulation are the primary mechanisms. Animal data further supports enhanced exercise endurance.
A randomized, double-blind, placebo-controlled multicenter study evaluated W. coagulans MTCC 5856 as adjunct therapy in children with acute diarrhea, finding good tolerability with no unexpected adverse events. The strain has GRAS status and pediatric safety data. IBS in children has also been studied with B. coagulans Unique IS-2.
An open-label fixed-dose study with B. coagulans SNZ 1969 in hyperlipidemia patients showed reduction in total serum cholesterol and LDL and increase in HDL. In-vitro studies with MTCC 5856 confirmed cholesterol-lowering activity. B. coagulans is noted to possess cholesterol-lowering effects through bile salt hydrolase activity.
B. coagulans consistently reduces inflammatory biomarkers (CRP, IL-6, myeloperoxidase, IL-17) across multiple RCTs in IBS, RA, IBD, and depression populations. Anti-inflammatory effects are attributed to downregulation of pro-inflammatory cytokines and upregulation of regulatory cytokines. Evidence across several conditions is robust.
B. coagulans has been evaluated in IBD populations including ulcerative colitis, with evidence of anti-inflammatory effects and symptom improvement. The organism reduces pro-inflammatory cytokines and abdominal symptoms in inflamed bowel conditions. Evidence is preliminary but grounded in clinical trials.
Randomized controlled trials demonstrate B. coagulans can improve constipation symptoms, stool frequency, and quality of life in adults. A double-blind RCT of W. coagulans BC99 (90 adults, 8 weeks) significantly increased spontaneous bowel movement frequency and reduced PAC-SYM scores. Drug-induced constipation associated with functional GI disorders has also been studied in an RCT with B. coagulans LBSC.
A randomized, double-blind, placebo-controlled, multi-centre pilot RCT (n=40, 90 days) found B. coagulans MTCC 5856 produced significant improvements (p=0.01) across multiple depression rating scales (HAM-D, MADRS, CES-D) in IBS patients with major depressive disorder. A separate 8-week RCT with W. coagulans BC99 also showed reductions in HAMD scores alongside gut microbiota shifts.
Multiple randomized controlled trials show B. coagulans reduces stool frequency and severity of diarrhea in IBS-D patients. A double-blind RCT with B. coagulans MTCC 5856 (2×10⁹ CFU/day, 90 days) significantly reduced diarrhea frequency vs. placebo. B. coagulans LMG S-31876 at 2 billion CFU/day over 8 weeks also produced significant decline in diarrhea symptoms. Pediatric acute diarrhea has also been studied with positive outcomes.
B. coagulans strains produce a range of digestive enzymes including proteases, lipases, and carbohydrate-metabolizing enzymes that facilitate nutrient digestion and absorption in the small intestine. This has been documented in mechanistic reviews and supported by the protein absorption RCT data with GBI-30, 6086.
B. coagulans metabolizes a broad range of dietary sugars (lactose, fructose, sorbitol, maltose, sucrose, inulin, mannan) rapidly within the small intestine, preventing their fermentation in the colon and the resultant GI symptoms associated with carbohydrate sensitivity and malabsorption. This mechanism is documented in both patent literature and mechanistic reviews.
Bacillus coagulans is a lactic acid-producing, spore-forming probiotic that modulates gut microbiota composition and has been evaluated in multiple randomized clinical trials for IBS, diarrhea, and gut health. It increases beneficial bacteria and SCFA production and demonstrates significant resilience in the GI tract due to its sporulation ability.
B. coagulans operates through the gut-brain axis, modulating gut microbiota to influence neurotransmitter levels (serotonin, GABA, dopamine), inflammatory cytokines, and short-chain fatty acids, with documented effects on depression, anxiety, and stress in clinical trials. Multiple RCTs have measured gut-brain axis biomarkers alongside psychological outcomes.
Bacillus coagulans has demonstrated IBS efficacy in multiple RCTs and meta-analyses. A 90-day RCT of B. coagulans MTCC 5856 (2 billion CFU/day) significantly improved bloating, diarrhea, abdominal pain, and stool frequency in IBS-D versus placebo. A 2025 strain-specific meta-analysis confirmed B. coagulans Unique IS2 and MTCC 5856 in meta-analyses of IBS symptom improvement and quality-of-life outcomes.
B. coagulans has been assessed in IBD patients in a randomized controlled trial, showing good GI tract survival and modulation of serum cytokines, serotonin, and dopamine. Animal evidence and clinical evidence from IBS studies also support anti-inflammatory effects relevant to IBD. The evidence base is emerging but not yet large-scale.
B. coagulans efficiently metabolizes lactose through a combination of extracellular enzymatic activity and intracellular metabolism, preventing undigested lactose from reaching the large intestine where it would cause fermentation and GI symptoms. This mechanism is documented in patent literature and referenced mechanistic reviews.
A crossover, diet-controlled RCT (n=29) demonstrated that B. coagulans GBI-30, 6086 co-administered with casein protein significantly increased perceived recovery at 24 and 72 hours and decreased soreness at 72 hours post-exercise vs. protein alone. CK levels showed a trend toward reduced muscle damage (p=0.08) with B. coagulans.
Clinical trial evidence shows B. coagulans GBI-30, 6086 co-administered with protein decreased muscle soreness at 72 hours post-exercise vs. protein alone in a crossover RCT. The Sports Medicine literature also confirms reduced perceived muscle soreness and increased recovery speeds in exercise studies with W. coagulans strains.
Animal studies with W. coagulans BC99 showed significantly increased exercise endurance, reduced fatigue biomarkers, elevated glycogen stores, and improved antioxidant enzyme levels in protein-supplemented fatigued mice. Human pilot data suggests maintained peak power output following exhaustive exercise when B. coagulans is combined with protein supplementation.
A randomized, double-blind, placebo-controlled pilot trial (n=45) found that B. coagulans GBI-30, 6086 added to standard RA therapy produced statistically significant improvement in Pain Scale (p=0.046) and greater improvements in patient global assessment, CRP, and functional capacity vs. placebo. The gut-immune axis is the proposed mechanistic link.
Bacillus coagulans is a spore-forming probiotic listed in clinical SIBO treatment guidelines due to its ability to survive stomach acid and reach the small intestine intact. A 2023 meta-analysis of RCTs found B. coagulans improved IBS symptoms—including abdominal pain and bloating—that commonly overlap with SIBO. It is included in Optimal DX SIBO clinical protocols.
A double-blind, placebo-controlled clinical trial (Frontiers in Nutrition, 2024) evaluated B. coagulans LMG S-31876 specifically for immunomodulation and stress in adults, finding measurable effects on stress-related parameters. The BCP92 RCT (n=100, 12 weeks) also reported significant stress relief as one of several measured outcomes.
A clinical study of B. coagulans SNZ 1969 combined with metronidazole in 120 women with bacterial vaginosis showed an 86.6% success rate in treating and minimizing recurrence. B. coagulans LMG S-24828 has been shown to impair Candida virulence and protect vaginal epithelial cells against infection in vitro. Clinical evidence for bacterial vaginosis treatment is documented.
Body systems that Bacillus coagulans may help support.
Go back